Skip to main content
Clinical Trials/KCT0006325
KCT0006325
Completed
未知

A prospective, randomized, comparative clinical trial to evaluate the efficacy and safety of SRT(Selective Retina Therapy) with 'R:GEN' in patients with Central Serous Chorioretinopathy

Overview

Phase
未知
Intervention
Not specified
Conditions
Diseases of the eye and adnexa
Sponsor
The Catholic University of Korea, Yeouido St. Mary's Hospital
Enrollment
44
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
January 21, 2019
Last Updated
4 years ago
Study Type
Interventional Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • In chronic CSC patients, as follows: (1\) the eye with persistent ( \= 3 months) subretinal fluid (SRF) involving the fovea in the optical coherence tomography (OCT) images of; (2\) focal or diffuse active hyperfluorescent leakages due to CSC on the fundus fluorescein angiography (FFA) image; (3\) between the age of 19 and 65 years.

Exclusion Criteria

  • (1\) the eye with best\-corrected visual acuity (BCVA) of 20/200 or worse (Snellen equivalent); (2\) other chorioretinal diseases such as choroidal neovascularization (CNV) and polypoidal choroidal vasculopathy (PCV); (3\) lens or vitreous opacity interrupting proper retinal imaging and laser treatment; (4\) RPE atrophy over 1,000 µm in diameter involving fovea; (5\) large PED over 300 µm in width or 100 µm in height; (6\) history of conventional laser photocoagulation or PDT for CSC; (7\) history of intravitreal injection of anti\-VEGF within 10 weeks prior to SRT; (8\) Use of systemic, periocular, intraocular corticosteroid within 1 year prior to SRT; (9\) use of spironolactone, acetazolamide, or ketoconazole within 2 months prior to SRT.

Outcomes

Primary Outcomes

Not specified

Similar Trials